Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Systolic hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    501 result(s) found for: Systolic hypertension. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-004534-24 Sponsor Protocol Number: 2007CV09 Start Date*: 2008-11-18
    Sponsor Name:University of Dundee
    Full Title: Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension?
    Medical condition: Isolated systolic hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050591 Isolated systolic hypertension LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001001-41 Sponsor Protocol Number: PR002-CLN-pro008 Start Date*: 2008-06-02
    Sponsor Name:Protherics Medicines Development Ltd, a BTG plc company
    Full Title: A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension
    Medical condition: Men and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10020772 Hypertension PT
    9.1 10042957 Systolic hypertension PT
    9.1 10012758 Diastolic hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001227-40 Sponsor Protocol Number: SMR-2271(SER100-001) Start Date*: 2013-09-23
    Sponsor Name:Serodus ASA
    Full Title: A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated ...
    Medical condition: Isolated Systolic Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10050591 Isolated systolic hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) FI (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003144-23 Sponsor Protocol Number: PANDA Start Date*: 2014-02-03
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment
    Medical condition: Chronic hypertension in pregnancy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10036695 Primary hypertension LLT
    16.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    16.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017831-16 Sponsor Protocol Number: 26169 Start Date*: 2010-07-15
    Sponsor Name:Institute of pharmacology, Aarhus university
    Full Title: Effects of 6 months intensive vasodilating treatment on vascular resistance and coronary flow reserve in hypertensive patients
    Medical condition: Essential Hypertension and changes in the vasculature related to high blood pressure.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    12.1 10015489 Essential hypertension, benign LLT
    12.1 10015491 Essential hypertension, unspecified LLT
    12.1 10020772 Hypertension LLT
    12.1 10020775 Hypertension arterial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004224-37 Sponsor Protocol Number: EREMIT Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Leipzig
    Full Title: Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie
    Medical condition: - steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis: - Cardiac index ≤ 2,1 l/min/m2 - 6 MWD ≤ 380 m - systolic RR...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001131-31 Sponsor Protocol Number: FHC-1-2012 Start Date*: 2012-06-14
    Sponsor Name:Department of Medical Research
    Full Title: Effekts of nebivolol on the nitric oxide system in patients with essentiel hypertension
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001283-10 Sponsor Protocol Number: NL80929.091.22 Start Date*: 2022-06-28
    Sponsor Name:Radboud University Medical Center
    Full Title: The effects of medication induced blood pressure reduction on cerebral hemodynamics in hypertensive frail elderly
    Medical condition: Hypertension
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004938-16 Sponsor Protocol Number: 00-MEP-04 Start Date*: 2008-02-19
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION.
    Medical condition: Mild to moderate hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001783-36 Sponsor Protocol Number: CLCZ696A2318 Start Date*: 2013-08-27
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized 8-week double-blind, parallel-group, active-controlled, multicenter study to evaluate efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in essential hypertensive...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003459-76 Sponsor Protocol Number: 09F401 Start Date*: 2015-02-03
    Sponsor Name:Istituto Auxologico Italiano, IRCCS
    Full Title: REducing blood pressure Variability in Essential hypertension with RAmipril vErsus Nifedipine GITS Trial
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000631-25 Sponsor Protocol Number: 2007-000631-25 Start Date*: 2010-06-08
    Sponsor Name:KAROLINSKA INSTITUTET
    Full Title: THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION
    Medical condition: ESSENTIAL HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    12.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011296-80 Sponsor Protocol Number: CSPP100AFR01 Start Date*: 2009-06-10
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients
    Medical condition: Hypertension artérielle systolique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042957 Systolic hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003071-37 Sponsor Protocol Number: QGC001/2QG1 Start Date*: 2014-11-14
    Sponsor Name:Quantum Genomics
    Full Title: Multicenter, randomized, double-blind, two-period, placebo controlled, forced-titration proof of concept crossover study to compare QGC001 with placebo in patients with grade I or II essential hype...
    Medical condition: Hyperactivity of the brain renin-angiotensin system participates to the development and maintenance of essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021987-13 Sponsor Protocol Number: NL29900.04 Start Date*: 2010-10-15
    Sponsor Name:University Medical Center Groningen
    Full Title: Renal Hemodynamic Effects of ALiskiren (rasilez) in comparison to ramipril (Tritrace) in patients with overweigHt/obeSiTy and UntreateD hYpertension: The renal HEALTH-STUDY
    Medical condition: Glomerular hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002422-29 Sponsor Protocol Number: 1235.8 Start Date*: 2007-10-19
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001014-37 Sponsor Protocol Number: ALTUM Start Date*: 2020-08-13
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Pharmacogenetics of hypertension: randomized monocentric study in patients with essential hypertension and treated with Spironolactone or Torasemide
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    22.1 10047065 - Vascular disorders 10015489 Essential hypertension, benign LLT
    21.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001823-20 Sponsor Protocol Number: CMA-0601-PR-0004 Start Date*: 2006-06-22
    Sponsor Name:CHIESI
    Full Title: A twelve-week, multicentre, double blind, randomised, parallel group, clinical study to assess the antihypertensive efficacy of delapril 15 mg b.i.d. and 30 mg b.i.d. versus lisinopril and placebo
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015488 Essential hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003567-31 Sponsor Protocol Number: KPUK0106 Start Date*: 2007-05-25
    Sponsor Name:Med. Klinik II, Grosshadern, Klinikum der Universität München
    Full Title: Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
    Medical condition: hypertension metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10052066 Metabolic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004235-31 Sponsor Protocol Number: SEVICONTROL-1 Start Date*: 2011-12-09
    Sponsor Name:IPPMed GmbH
    Full Title: SEVICONTROL-1: Efficacy and safety of a fixed combination of olmesartan 40 mg/amlodipin 10 mg in patients with moderate essential hypertension not sufficiently controlled under monotherapy with can...
    Medical condition: moderate essential arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10015491 Essential hypertension, unspecified LLT
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:38:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA